Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Melisi

Showing results (31-40 of 128) with videos related to

Pageof 13
Sort By:
ESMO Open|January 21, 2020
First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review studyJulien Taieb, Gerald W Prager, Davide Melisi, et al.
Anticancer Research|August 1, 2018
CT Texture Analysis of Ductal Adenocarcinoma Downstaged After ChemotherapyValentina Ciaravino, Nicolò Cardobi, Riccardo DE Robertis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2011
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotypeCarmine Carbone, Tania Moccia, Cihui Zhu, et al.
European Journal of Clinical Nutrition|March 28, 2018
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapyIlaria Trestini, Luisa Carbognin, Isabella Sperduti, et al.
Journal of Gastric Cancer|January 4, 2020
Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric CancerAlessandro Cavaliere, Valeria Merz, Simona Casalino, et al.
Abdominal Radiology (New York)|April 9, 2020
Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinomaRiccardo De Robertis, Alessandro Beleù, Nicolò Cardobi, et al.
Translational Oncology|July 13, 2026
CT texture analysis and delta radiomics in predicting R0 resection after preoperative chemotherapy in resectable pancreatic ductal adenocarcinomaRiccardo De Robertis, Nicolò Cardobi, Flavio Spoto, et al.
Journal of the National Cancer Institute|July 12, 2011
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1Davide Melisi, Qianghua Xia, Genni Paradiso, et al.
Molecular Cancer Therapeutics|April 17, 2008
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasisDavide Melisi, Satoshi Ishiyama, Guido M Sclabas, et al.
Clinical Drug Investigation|July 19, 2022
Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case ReportsAlberto Quinzii, Camilla Zecchetto, Simona Casalino, et al.
Pageof 13

Showing results (31-40 of 128) with videos related to

Sort By:
Pageof 13
ESMO Open|January 21, 2020
First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review studyJulien Taieb, Gerald W Prager, Davide Melisi, et al.
Anticancer Research|August 1, 2018
CT Texture Analysis of Ductal Adenocarcinoma Downstaged After ChemotherapyValentina Ciaravino, Nicolò Cardobi, Riccardo DE Robertis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2011
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotypeCarmine Carbone, Tania Moccia, Cihui Zhu, et al.
European Journal of Clinical Nutrition|March 28, 2018
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapyIlaria Trestini, Luisa Carbognin, Isabella Sperduti, et al.
Journal of Gastric Cancer|January 4, 2020
Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric CancerAlessandro Cavaliere, Valeria Merz, Simona Casalino, et al.
Abdominal Radiology (New York)|April 9, 2020
Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinomaRiccardo De Robertis, Alessandro Beleù, Nicolò Cardobi, et al.
Translational Oncology|July 13, 2026
CT texture analysis and delta radiomics in predicting R0 resection after preoperative chemotherapy in resectable pancreatic ductal adenocarcinomaRiccardo De Robertis, Nicolò Cardobi, Flavio Spoto, et al.
Journal of the National Cancer Institute|July 12, 2011
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1Davide Melisi, Qianghua Xia, Genni Paradiso, et al.
Molecular Cancer Therapeutics|April 17, 2008
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasisDavide Melisi, Satoshi Ishiyama, Guido M Sclabas, et al.
Clinical Drug Investigation|July 19, 2022
Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case ReportsAlberto Quinzii, Camilla Zecchetto, Simona Casalino, et al.
Pageof 13